Tarsus Pharmaceuticals (TARS) EBT (2019 - 2026)

Tarsus Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, EBT rose 81.92% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at -$43.6 million (up 57.58% YoY), while the FY2025 annual figure was -$64.4 million, up 44.3% from the prior year.
• EBT was -$4.5 million for Q1 2026 at Tarsus Pharmaceuticals, up from -$6.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$4.5 million in Q1 2026 to a low of -$42.5 million in Q4 2023.
• Historically, EBT has averaged -$22.3 million across 5 years, with a median of -$23.1 million in 2024.
• The sharpest annual moves came in 2023 and 2026: EBT slumped 474.12% in 2023, then jumped 81.92% in 2026.
• A 5-year view of EBT shows it stood at -$13.6 million in 2022, then slumped by 211.62% to -$42.5 million in 2023, then surged by 45.63% to -$23.1 million in 2024, then surged by 72.97% to -$6.2 million in 2025, then rose by 27.44% to -$4.5 million in 2026.
• The last three EBT figures came in at -$4.5 million (Q1 2026), -$6.2 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.